Characteristic of the studies included in the meta-analysis
| First Author | Year | Country | No. of case | Gender F/M | Age | Infliximab dose (mg/kg) | Infliximab treatment time (weeks) |
|---|---|---|---|---|---|---|---|
| Hiroyuki Tanaka | 2009 | Japan | 22 | 2/20 | 39.9±12.9 | – | – |
| Tsutomu Sakai | 2012 | Japan | 20 | 8/12 | 45±14 | 5 | 0, 2, 6, and every 8 weeks |
| Toshikatsu Kaburaki | 2014 | Japan | 150 | 32/118 | 38.5±12.1 | – | – |
| Vanesa Calvo-Rĺo | 2014 | Spain | 124 | 56/68 | 38.6±10.4 | 3–5 | 0, 2, 6, and every 4–8 weeks |
| Sultan Al Rashidi | 2013 | Saudi Arabia | 19 | 1/18 | 25.6±7.8 | 5 | 0, 2, 6, and every 8 weeks |
| L. Niccol | 2007 | Italy | 12 | 5/7 | 33±12.8 | 5 | 0, 2, 6, and every 8 weeks |
| Daiju Iwata | 2012 | Japan | 17 | 3/14 | 36.9 (15–58) | 5 | 0, 2, 6, and every 8 weeks |
| Fabrizio Cantini | 2012 | Italy | 36 | 21/15 | 31.6±10.9 | 5 | 0, 2, 6, and every 8 weeks |
| Ilknur Tugal-Tutkun | 2005 | Turkey | 13 | 0/13 | 18–65 | 5 | 0, 2, 6, and 14 |